## Ignacio GarcÃ-a-Tuñón Llanio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9459288/publications.pdf

Version: 2024-02-01

43 papers 1,571 citations

<sup>361413</sup>
20
h-index

315739 38 g-index

46 all docs

46 docs citations

46 times ranked

2774 citing authors

#	Article	IF	CITATIONS
1	A novel nonsense variant in TPM4 caused dominant macrothrombocytopenia, mild bleeding tendency and disrupted cytoskeleton remodeling. Journal of Thrombosis and Haemostasis, 2022, 20, 1248-1255.	3.8	3
2	CRISPR/Cas9-Directed Gene Trap Constitutes a Selection System for Corrected BCR/ABL Leukemic Cells in CML. International Journal of Molecular Sciences, 2022, 23, 6386.	4.1	3
3	Loss of HDAC11 accelerates skeletal muscle regeneration in mice. FEBS Journal, 2021, 288, 1201-1223.	4.7	14
4	Characterization of the Platelet Phenotype Caused by a Germline RUNX1 Variant in a CRISPR/Cas9-Generated Murine Model. Thrombosis and Haemostasis, 2021, 121, 1193-1205.	3.4	5
5	Future Approaches for Treating Chronic Myeloid Leukemia: CRISPR Therapy. Biology, 2021, 10, 118.	2.8	9
6	Priming human adiposeâ€derived mesenchymal stem cells for corneal surface regeneration. Journal of Cellular and Molecular Medicine, 2021, 25, 5124-5137.	3.6	18
7	Biological significance of monoallelic and biallelic BIRC3 loss in $del(11q)$ chronic lymphocytic leukemia progression. Blood Cancer Journal, 2021, $11,127.$	6.2	12
8	Granuloma Formation in a Cyba-Deficient Model of Chronic Granulomatous Disease Is Associated with Myeloid Hyperplasia and the Exhaustion of B-Cell Lineage. International Journal of Molecular Sciences, 2021, 22, 8701.	4.1	3
9	CRISPR-Cas9 Technology as a Tool to Target Gene Drivers in Cancer: Proof of Concept and New Opportunities to Treat Chronic Myeloid Leukemia. CRISPR Journal, 2021, 4, 519-535.	2.9	3
10	Establishment of a conditional Nomo1 mouse model by CRISPR/Cas9 technology. Molecular Biology Reports, 2020, 47, 1381-1391.	2.3	6
11	CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition. Leukemia, 2020, 34, 1599-1612.	7.2	21
12	ETV6/RUNX1 Fusion Gene Abrogation Decreases the Oncogenicity of Tumour Cells in a Preclinical Model of Acute Lymphoblastic Leukaemia. Cells, 2020, 9, 215.	4.1	16
13	<i>Cyba</i> -deficient mice display an increase in hematopoietic stem cells and an overproduction of immunoglobulins. Haematologica, 2020, 106, 142-153.	3.5	7
14	Biological Impact of Monoallelic and Biallelic BIRC3 Loss in Del(11q) Chronic Lymphocytic Leukemia Progression. Blood, 2020, 136, 4-4.	1.4	0
15	FRI-422-Genetic and pathophysiological factors leading to deficient acyl-CoA oxidase 2 (ACOX2) activity in hepatocytes, an alteration which causes oxidative and endoplasmic reticulum stress in liver cells. Journal of Hepatology, 2019, 70, e579.	3.7	O
16	Splice donor site sgRNAs enhance CRISPR/Cas9-mediated knockout efficiency. PLoS ONE, 2019, 14, e0216674.	<b>2.</b> 5	19
17	Targeted genome editing in acute lymphoblastic leukemia: a review. BMC Biotechnology, 2018, 18, 45.	3.3	13
18	CRISPR/Cas9-Generated Models Uncover Therapeutic Vulnerabilities of Del(11q) Chronic Lymphocytic Leukemia Cells to Dual BCR and PARP Inhibition. Blood, 2018, 132, 948-948.	1.4	17

#	Article	IF	Citations
19	The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of <i>BCR/ABL in vitro</i> and in a xenograft model of chronic myeloid leukemia. Oncotarget, 2017, 8, 26027-26040.	1.8	30
20	C14ORF39/SIX6OS1 is a constituent of the synaptonemal complex and is essential for mouse fertility. Nature Communications, 2016, 7, 13298.	12.8	80
21	Adipose-Derived Mesenchymal Stem Cell Administration Does Not Improve Corneal Graft Survival Outcome. PLoS ONE, 2015, 10, e0117945.	2.5	39
22	Biointegration of corneal macroporous membranes based on poly(ethyl acrylate) copolymers in an experimental animal model. Journal of Biomedical Materials Research - Part A, 2015, 103, 1106-1118.	4.0	31
23	STAG3 is a strong candidate gene for male infertility. Human Molecular Genetics, 2014, 23, 3421-3431.	2.9	69
24	Mutant Cohesin in Premature Ovarian Failure. New England Journal of Medicine, 2014, 370, 943-949.	27.0	244
25	Pluripotent Stem Cells of the Mammalian Early Embryo. , 2013, , 107-119.		0
26	Meiotic cohesin complexes are essential for the formation of the axial element in mice. Journal of Cell Biology, 2012, 197, 877-885.	5.2	100
27	Association of Rex-1 to target genes supports its interaction with Polycomb function. Stem Cell Research, 2011, 7, 1-16.	0.7	18
28	Pro-inflammatory cytokines and prostate-specific antigen in hyperplasia and human prostate cancer. Cancer Detection and Prevention, 2008, 32, 23-32.	2.1	71
29	OSM, LIF, Its Receptors, and Its Relationship with the Malignance in Human Breast Carcinoma ( <i>In) Tj ETQq<math>1\ 1</math></i>	0.784314	rgBT /Overl
30	P5. A dual osteoclastic and metalloproteolytic mechanism is required for bone colonization in lung cancer metastasis. Cancer Treatment Reviews, 2008, 34, 14-15.	7.7	0
31	A Novel Lung Cancer Signature Mediates Metastatic Bone Colonization by a Dual Mechanism. Cancer Research, 2008, 68, 2275-2285.	0.9	89
32	Influence of IFN-gamma and its receptors in human breast cancer. BMC Cancer, 2007, 7, 158.	2.6	44
33	Cell Cycle Control Related Proteins (p53,p21, and Rb) and Transforming Growth Factorβ(TGFβ) in Benign and Carcinomatous (In Situ and Infiltrating) Human Breast: Implications in Malignant Transformations. Cancer Investigation, 2006, 24, 119-125.	1.3	14
34	The p38 transduction pathway in prostatic neoplasia. Journal of Pathology, 2006, 208, 401-407.	4.5	83
35	Role of tumor necrosis factor-α and its receptors in human benign breast lesions and tumors (inÂsituand infiltrative). Cancer Science, 2006, 97, 1044-1049.	3.9	56
36	P38 MAPK protects against TNF- $\hat{l}_{\pm}$ -provoked apoptosis in LNCaP prostatic cancer cells. Apoptosis: an International Journal on Programmed Cell Death, 2006, 11, 1969-1975.	4.9	45

#	Article	IF	CITATIONS
37	IL-6, its receptors and its relationship with bcl-2 and bax proteins in infiltrating and in situ human breast carcinoma. Histopathology, 2005, 47, 82-89.	2.9	61
38	Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate. Journal of Pathology, 2004, 202, 41-49.	4.5	100
39	Interleukin-1 (IL- $\hat{1}$ ± and IL- $\hat{1}$ 2) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma. Cancer, 2004, 100, 1388-1396.	4.1	81
40	Pro-Apoptotic Tumor Necrosis Factor-α Transduction Pathway In Normal Prostate, Benign Prostatic Hyperplasia And Prostatic Carcinoma. Journal of Urology, 2003, 170, 787-790.	0.4	26
41	Interleukin-2 and its receptor complex ( $\hat{l}_{\pm}$ , $\hat{l}_{\pm}^2$ and $\hat{l}_{\pm}^3$ chains) in in situand infiltrative human breast cancer: an immunohistochemical comparative study. Breast Cancer Research, 2003, 6, R1-7.	5.0	53
42	Control of the annual testicular cycle of the marbled-newt by p53, p21, and Rb gene products. Molecular Reproduction and Development, 2002, 63, 202-209.	2.0	17
43	CRISPR-ERA for Switching Off (Onco) Genes. , 0, , .		3